Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.
John Edwards, newly-appointed CEO of Verseau Therapeutics, is continually searching for something special.
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson’s disease and other neurodegenerative conditions.
Valo Health is the latest company to go public through a merger with a special purpose acquisition company. It will merge with Khosla Ventures Acquisition Co. and begin to trade on the Nasdaq.
BioSpace recently spoke with Mir Imran, CEO and Chief Innovator at Rani Therapeutics, a company developing and testing a “robotic” pill that delivers biologics orally.
BioSpace caught up with Charles Fuchs, M.D., SVP, Global Head of Oncology & Hematology Product Development, Genentech during the ASCO meeting on personalized cancer care.
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
The $7 billion transaction by Datavant with Ciox Health will be the nation’s largest “neutral and secure health data ecosystem.”
Despite controversy over the drug’s effectiveness, it appears to have spiked interest in investing in Alzheimer’s drug companies, something that had been on the decline for several years.
Unicorn Hunters is a new Internet reality show where startup companies can pitch a group of well-known panelists dubbed the “Circle of Money” which allows for a kind of crowdsourced funding appeal.